CNS Pharmaceuticals. – Consensus Indicates Potential 307.6% Upside

Broker Ratings

CNS Pharmaceuticals. with ticker code (CNSP) have now 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 8 and 7 calculating the mean target price we have 7.5. Now with the previous closing price of 1.84 this is indicating there is a potential upside of 307.6%. There is a 50 day moving average of 2.11 while the 200 day moving average is 1.99. The company has a market cap of $45m. Visit the company website at:

CNS Pharmaceuticals., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. CNS Pharmaceuticals. was founded in 2017 and is based in Houston, Texas.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp

AIM All Share Index